Abstract
Melanoma is an aggressive form of skin cancer which is the cause of a great number of skin cancer-related deaths worldwide and about 300 deaths in Denmark. After several years of failure of treatment of metastatic melanoma, the development of BRAF- and later MEK inhibitors was considered revolutionary. Treatment with BRAF inhibitors alone and especially in combination with a MEK inhibitor improves outcome for patients with BRAF V600-mutated metastatic melanoma. However, even when treated with the combination of the inhibitors, many patients develop acquired resistance within a year.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Drug Resistance, Neoplasm
-
Humans
-
Imidazoles / therapeutic use
-
Melanoma* / drug therapy
-
Melanoma* / genetics
-
Melanoma* / secondary
-
Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors*
-
Mitogen-Activated Protein Kinase Kinases / genetics
-
Mutation
-
Oximes / therapeutic use
-
Prognosis
-
Protein Kinase Inhibitors / therapeutic use
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
-
Proto-Oncogene Proteins B-raf / genetics
-
Pyridones / therapeutic use
-
Pyrimidinones / therapeutic use
-
Skin Neoplasms* / drug therapy
-
Skin Neoplasms* / genetics
-
Skin Neoplasms* / secondary
Substances
-
Antineoplastic Agents
-
Imidazoles
-
Oximes
-
Protein Kinase Inhibitors
-
Pyridones
-
Pyrimidinones
-
trametinib
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
Mitogen-Activated Protein Kinase Kinases
-
dabrafenib